- 2026 net product revenue guidance: $4.7B-$5.1B
- Guidance issued alongside Q3 2026 earnings release
Alnylam Pharmaceuticals reiterated its 2026 net product revenue outlook of $4.7 billion to $5.1 billion. The guidance was maintained alongside the company's third-quarter earnings release.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.